China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

Will $1bn Lead To First Domestic mRNA Vaccine?

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

Sand running through an hourglass
CHINA RUSHES TO DEVELOP VACCINES FOR OMICRON VARIANT, GIVING $300m MORE TO ABOGEN • Source: Alamy

Among the first countries globally to develop a COVID-19 vaccine, China is now kicking into high gear again to develop a new vaccine to fend off the still-emerging omicron variant, formally deemed to be a “virus of concern” by the World Health Organization.

Since the delta variant emerged and spread across the globe, the protection offered by various types of existing vaccines has been in the spotlight

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia